Arguably, isoforms of phosphorylated tau (p-tau) such as p-tau threonine 181, 231 and 217 in the blood, which correlate with cerebral tauopathy and cerebral Aβ positivity, provide more robust biomarkers of AD exhibiting large fold-changes in plasma in disease [5,6,8]. This evidence concerns the gene MAPT and Alzheimer disease.